Israel Englander Kronos Bio, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,425,065 shares of KRON stock, worth $969,044. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,425,065

Previous 1,716,501 16.98%

Holding current value

$969,044

Previous $1.63 Million 28.34%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.82 - $1.07 $238,977 - $311,836	-291,436 Reduced 16.98%	1,425,065 $1.17 Million
Q4 2024 Feb 14, 2025	SELL	$0.82 - $1.07 $270,027 - $352,353	-329,302 Reduced 16.1%	1,716,501 $1.63 Million
Q3 2024 Nov 14, 2024	BUY	$0.92 - $1.5 $172,789 - $281,722	187,815 Added 10.11%	2,045,803 $2.05 Million
Q2 2024 Aug 14, 2024	BUY	$0.73 - $1.38 $22,093 - $41,765	30,265 Added 1.66%	1,857,988 $2.3 Million
Q1 2024 May 15, 2024	BUY	$1.02 - $1.3 $999,317 - $1.27 Million	979,723 Added 115.53%	1,827,723 $2.38 Million
Q4 2023 Feb 14, 2024	BUY	$0.75 - $1.49 $154,760 - $307,457	206,347 Added 32.16%	848,000 $1.06 Million
Q2 2023 Aug 14, 2023	SELL	$1.24 - $1.92 $14,775 - $22,878	-11,916 Reduced 1.82%	641,653 $1.1 Million
Q1 2023 May 15, 2023	BUY	$1.34 - $2.62 $240,148 - $469,543	179,215 Added 37.78%	653,569 $954,000
Q4 2022 Feb 14, 2023	BUY	$1.44 - $3.44 $277,119 - $662,007	192,444 Added 68.26%	474,354 $768,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $4,170 - $6,909	-1,245 Reduced 0.44%	281,910 $944,000

Others Institutions Holding KRON

# of Institutions

Shares Held

19.3M

Call Options Held

51.2K

Put Options Held

View Full List

About Kronos Bio, Inc.

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $38.6M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

More about KRON

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account